The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

CROWN

18th Oct 2024

5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer

This summary shows the updated results of an ongoing research study called CROWN that was published in The Lancet Respiratory Medicine in December 2022. In the CROWN study, researchers looked at the effects of two study medicines called lorlatinib and crizotinib. The study included people with advanced non-small-cell lung cancer (NSCLC) that had not been treated previously. All people in the study had cancer cells with changes (known as alterations) in a gene called anaplastic lymphoma kinase, or ALK. This ALK gene is involved in cancer growth. In this updated study, researchers looked at the continued benefit in people who took lorlatinib compared with people who took crizotinib after 3 years.

21st Jun 2023

CROWN

5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer

Plain Language Summary: updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer